GILD vs SMMT · P/E 18, rev $7.80B vs $11.46B cap
Gilead Sciences Inc (GILD) versus Summit Therapeutics PLC (SMMT) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Summit Therapeutics PLC (SMMT) is a biotechnology company listed on US.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
SMMT does not have a complete income-statement cache yet.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. SMMT currently screens at market cap $11.46B.
Not investment advice. Open the GILD and SMMT stock pages for the full models.
Not investment advice.